Recital 38, Decision_act (EU) 2018/9019

In forcesince 29 Oct 2018

In light of the foregoing and taking the results of the market investigation and all

the evidence available to it into account, the Commission considers that the

insufficiency, (xii) regulation of lipid metabolism in the case of hyperlipidaemia, (xiii) reduction of copper in the liver, (xiv) reduction of excessive body weight, (xv) nutritional restoration, convalescence, (xvi) support of skin function in the case of dermatosis and excessive loss of hair.

43 Regulation (EC) No. 767/2009 of the European Parliament and of the Council on the placing on the market and use of feed (OJ L 229, 1.9.2009, p.1).

44 Form CO, paragraph 146; Responses to RFI to Competitors, question 7; Minutes of a call with a competitor, 13 September 2018, 10.00 CET.

45 Response to RFI to Competitors, question 7.

46 Form CO, paragraph 146 and footnote 103; Parties' response to RFI 1, question 2, paragraph 2.17 and footnote 65; Form CO, paragraph 149.

47 Form CO, paragraph 149; Parties' response to RFI 2, question 4, paragraph 4.3.

48 Responses to RFI to Competitors, question 12. manufacture and supply of dietetic pet food constitutes a distinct relevant product market, separate from the market for the manufacture and supply of non-dietetic pet food.

5.2.2. Relevant geographic market definition 5.2.2.1.The Notifying Party's arguments